Purpose: Lung allocation policy is significant in determining lung transplantations (LTx). This study aims to evaluate the impact of LTx policy changes on geographic disparities in allocation and waitlist mortality (WLM).

Purpose: Earlier studies have examined the relationship between donor-recipient race-matching (RM) in lung transplantations (LTx). We aim to update the findings using all available lung transplant data from Organ Procurement and Transplant Network (OPTN) as of September 1, 2022.

Purpose: Over 47,000 people are living with Fontan Circuit in the US & Europe. Many adults with Fontan circulation require orthotopic heart transplant (OHT) or combined heart-liver transplantation (CHLT) often due to Fontan Associated Liver Disease (FALD). With no clear guidelines, we investigated our institutional experience of transplant in Fontan patients with FALD.

Purpose: Short-term mechanical circulatory support (MCS) plays an increasing role in patients in acute cardiogenic shock as a bridge-to-decision strategy for potential left ventricular assist device (LVAD) implantation.Microaxial flow pump (MFP) therapy thereby is gaining increasing importance as a complement to venoarterial extracorporeal membrane oxygenation (VA-ECMO) therapy for left ventricular unloading.The aim of the study was to compare VA-ECMO vs. VA-ECMO + MFP therapy as short-term MCS prior to LVAD implantation.Methods: 183 patients with advanced heart failure underwent LVAD implantation at our center between 2010 -2020.Of these, 34 patients had short-term MCS with VA-ECMO (n=16, group 1) or VA-ECMO + MFP (n=18, group 2) before LVAD implantation.Data were retrospectively analysed.Results: Both groups consisted only of patients in acute cardiogenic shock (INTERMACS profile 1 + 2, age (group 1 vs. group 2: 50.1 §9.8 vs. 52.7 § 7.3 years, p=0.1)).Short-term MCS was performed until LVAD implantation.Time on short-term MCS (6.6 §3.8 vs. 8 §4.9 days, p=0.4) showed no significant difference between the groups.Implanted permanent devices were HVAD and Heart Mate 3 (HM3) (group 1: HVAD: 88%, HM3: 12%; group 2: HVAD: 55%, HM3: 45%).Procedural characteristics showed no significant differences in terms of access, procedure time or volume management.Rates of in-hospital stroke (5.5 vs. 0%, p=1.0) and major bleeding (0 vs. 0%, p=1.0) were low in both groups.Rate of concomitant temporary RVAD implantation was similar in both groups (43.7 vs. 38.8%,p=1.0).Consecutive right heart failure in the first 3 months occurred in both groups (6,3 vs.5.5%, p=1.0).30-day (12.5 vs. 17%, p=1.0) and 1-year mortality (31.3 vs. 22.2%, p=0.7) revealed no significant differences between groups. Conclusion:Our study shows a similar outcome after short-term MCS and LVAD implantation in both groups resulting in a 30-day survival of >80% in our high-risk cohorts.The effect of additional MFP needs to be proven in further studies.